Soriano Amata Amy, de Cristofaro Tiziana, Di Palma Tina, Dotolo Serena, Gokulnath Priyanka, Izzo Antonella, Calì Gaetano, Facchiano Angelo, Zannini Mariastella
1IEOS, Institute of Experimental Endocrinology and Oncology 'G, Salvatore'-National Research Council, Naples, Italy.
2Dpt. of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Cancer Cell Int. 2019 Nov 20;19:303. doi: 10.1186/s12935-019-1022-8. eCollection 2019.
Ovarian cancer is the third most common cause of death among gynecologic malignancies worldwide. Understanding the biology and molecular pathogenesis of ovarian epithelial tumors is key to developing improved prognostic indicators and effective therapies. We aimed to determine the effects of PAX8 expression on the migrative, adhesive and survival capabilities of high-grade serous carcinoma cells.
PAX8 depleted Fallopian tube secretory cells and ovarian cancer cells were generated using short interfering siRNA. resistance, cell migration and adhesion properties of PAX8 silenced cells were analyzed by means of specific assays. Chromatin immunoprecipitation (ChIP) was carried out using a PAX8 polyclonal antibody to demonstrate that PAX8 is able to bind to the 5'-flanking region of the ITGB3 gene positively regulating its expression.
Here, we report that RNAi silencing of PAX8 sensitizes non-adherent cancer cells to and affects their tumorigenic properties. We show that PAX8 plays a critical role in migration and adhesion of both Fallopian tube secretory epithelial cells and ovarian cancer cells. Inhibition of PAX8 gene expression reduces the ability of ovarian cancer cells to migrate and adhere to the ECM and specifically to fibronectin and/or collagen substrates. Moreover, loss of PAX8 strongly reduces ITGB3 expression and consequently the correct expression of the αvβ3 heterodimer on the plasma membrane.
Our results demonstrate that PAX8 modulates the interaction of tumor cells with the extracellular matrix (ECM). Notably, we also highlight a novel pathway downstream this transcription factor. Overall, PAX8 could be a potential therapeutic target for high-grade serous carcinoma.
卵巢癌是全球妇科恶性肿瘤中第三大常见死因。了解卵巢上皮肿瘤的生物学和分子发病机制是开发改进的预后指标和有效治疗方法的关键。我们旨在确定PAX8表达对高级别浆液性癌细胞迁移、黏附和存活能力的影响。
使用短干扰siRNA生成PAX8缺失的输卵管分泌细胞和卵巢癌细胞。通过特定检测分析PAX8沉默细胞的耐药性、细胞迁移和黏附特性。使用PAX8多克隆抗体进行染色质免疫沉淀(ChIP),以证明PAX8能够与ITGB3基因的5'侧翼区域结合,正向调节其表达。
在此,我们报告PAX8的RNAi沉默使非贴壁癌细胞对[具体内容缺失]敏感,并影响其致瘤特性。我们表明PAX8在输卵管分泌上皮细胞和卵巢癌细胞的迁移和黏附中起关键作用。抑制PAX8基因表达会降低卵巢癌细胞迁移和黏附于细胞外基质(ECM)以及特异性黏附于纤连蛋白和/或胶原蛋白底物的能力。此外,PAX8的缺失强烈降低ITGB3表达,从而导致质膜上αvβ3异二聚体的正确表达缺失。
我们的结果表明PAX8调节肿瘤细胞与细胞外基质(ECM)的相互作用。值得注意的是,我们还突出了该转录因子下游的一条新途径。总体而言,PAX8可能是高级别浆液性癌的潜在治疗靶点。